Boston Scientific (NYSE: BSX ) announced that it had bought Bayer's (NASDAQOTH: BAYRY ) interventional division for $415 million last Thursday. The division, which makes products that help treat blood flow issues, makes sense as a bolt-on to Boston Scientific's peripheral interventional division. As the Minneapolis Star Tribune reports, this will give Boston roughly 40% share in the thrombectomy market when the deal closes in the second half of 2014. But why did Bayer make the sale?
In this video, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson talk about the acquisition, what motivated it for Boston and Bayer, and what investors should look for moving forward.
Is Boston Scientific a top dividend stock?
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.